In the first half (H1) of 2025, Abbott Laboratories performed well in the US medical device sector, with steady growth in its core product lines. According to leading data and analytics company GlobalData, some of Abbott’s high-volume product lines declined in average selling price (ASP) in the first six months of 2025, when compared to reporting from the same period last year. However, Abbott’s top revenue product lines maintained consistent ASPs across 2024 and 2025, which suggests that the company remains well-positioned and resistant to economic pressures, including those related to evolving tariff policies. When analysing Abbott’s highest-volume products, some nuances emerge. Products that ranked highest by volume of sales in 2024 experienced modest increases in ASPs while those leading by volume in 2025 showed no change or a slight decline in ASPs. This pattern may reflect changing purchasing strategies among US healthcare facilities, potentially arising due to evolving priorities in public health and cost considerations. According to its recent financial report, Abbott delivered a strong first half in 2025, with its US medical device sales growing by 14.8% compared to H1 2024. GlobalData’s latest data indicates continued strong performance across several key product lines, including MitraClip, Ensite X, and Tactiflex. In the US cardiovascular market, Abbott holds approximately 18% market share, according to GlobalData. Abbott’s US diagnostics saw a modest decline in year-over-year sales in the second quarter of 2025, specifically in point-of-care and rapid diagnostics. This appears to be linked to reduced demand for Covid-19 testing, which had previously seen high demand. This shift in demand could be responsible for the changes in some of Abbott’s high-volume sales. "Abbott Laboratories shows growth in core products amid market shifts" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments
Abbott Laboratories shows growth in core products amid market shifts
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...